Skip to main content
Midas Edge

Pulmonx Corp

For the period ended Sep 30, 2026. Filed Nov 3, 2026.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2026 · Filed Nov 3, 2026

LUNG$2.800.0%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Condensed Consolidated Statements of Stockholders’ Equity

(in thousands, except share amounts)

Common Stock · Additional Paid-In Capital · Accumulated Other Comprehensive Income · Accumulated Deficit · Total Stockholders’ Equity
Shares · Amount
Balances at January 1, 202641,673,648$42$573,272$2,360$(521,558)$54,116
Issuance of common stock upon vesting of restricted stock units379,781—————
Issuance of common stock upon exercise of stock options26,584—40——40
Issuance of shares pursuant to employee stock purchase plan157,190—201——201
Issuance of common stock warrant——1,105——1,105
Stock-based compensation expense——4,144——4,144
Currency translation adjustment———(191)—(191)
Net loss————(13,654)(13,654)
Balances at March 31, 202642,237,20342578,7622,169(535,212)45,761
Issuance of common stock upon vesting of restricted stock units711,0661(1)———
Stock-based compensation expense——3,635——3,635
Currency translation adjustment———(120)—(120)
Net loss————(10,080)(10,080)
Balances at June 30, 202642,948,26943582,3962,049(545,292)39,196
Issuance of common stock upon vesting of restricted stock units438,4521(1)———
Issuance of common stock upon exercise of stock options3,282—5——5
Issuance of shares pursuant to employee stock purchase plan160,662—202——202
Stock-based compensation expense——3,525——3,525
Currency translation adjustment———(334)—(334)
Net loss————(8,394)(8,394)
Balances at September 30, 202643,550,665$44$586,127$1,715$(553,686)$34,200
Common Stock · Additional Paid-In Capital · Accumulated Other Comprehensive Income · Accumulated Deficit · Total Stockholders’ Equity
Shares · Amount
Balances at January 1, 202539,785,969$40$551,211$2,113$(467,555)$85,809
Issuance of common stock upon vesting of restricted stock units310,403—————
Issuance of common stock upon exercise of stock options51,899—110——110
Issuance of shares pursuant to employee stock purchase plan99,209—554——554
Stock-based compensation expense——5,553——5,553
Currency translation adjustment———111—111
Change in unrealized losses on marketable securities———(22)—(22)
Net loss————(14,448)(14,448)
Balances at March 31, 202540,247,48040557,4282,202(482,003)77,667
Issuance of common stock upon vesting of restricted stock units477,5341———1
Issuance of common stock upon exercise of stock options18,792—27——27
Stock-based compensation expense——6,134——6,134
Currency translation adjustment———435—435
Change in unrealized losses on marketable securities———(1)—(1)
Net loss————(15,173)(15,173)
Balances at June 30, 202540,743,80641563,5892,636(497,176)69,090
Issuance of common stock upon vesting of restricted stock units349,129—————
Issuance of common stock upon exercise of stock options2,900—5——5
Issuance of shares pursuant to employee stock purchase plan150,699—200——200
Stock-based compensation expense——5,093——5,093
Currency translation adjustment———(399)—(399)
Change in unrealized gains on marketable securities———1—1
Net loss————(13,957)(13,957)
Balances at September 30, 202541,246,534$41$568,887$2,238$(511,133)$60,033
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.